Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 2 | 7 |
| 2006 | 5 | 8 | 13 |
| 2007 | 5 | 7 | 12 |
| 2008 | 7 | 7 | 14 |
| 2009 | 10 | 5 | 15 |
| 2010 | 16 | 14 | 30 |
| 2011 | 12 | 10 | 22 |
| 2012 | 22 | 7 | 29 |
| 2013 | 23 | 10 | 33 |
| 2014 | 17 | 9 | 26 |
| 2015 | 19 | 15 | 34 |
| 2016 | 15 | 12 | 27 |
| 2017 | 9 | 16 | 25 |
| 2018 | 15 | 11 | 26 |
| 2019 | 12 | 12 | 24 |
| 2020 | 6 | 11 | 17 |
| 2021 | 15 | 9 | 24 |
| 2022 | 3 | 13 | 16 |
| 2023 | 1 | 11 | 12 |
| 2024 | 4 | 8 | 12 |
| 2025 | 6 | 4 | 10 |
| 2026 | 6 | 3 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood Adv. 2026 09 08; 10(17):5821-5827.
-
Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis. J Neurooncol. 2026 Jul 15; 178(3).
-
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy. Leuk Lymphoma. 2026 Aug; 67(10):2064-2072.
-
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leuk Lymphoma. 2026 Jun; 67(7):1587-1594.
-
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity Probes. J Am Chem Soc. 2026 04 01; 148(12):12641-12654.
-
Ruxolitinib and heart failure outcomes among patients with myelofibrosis. Leuk Lymphoma. 2026 May; 67(6):1335-1342.
-
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. J Natl Compr Canc Netw. 2026 03; 24(3):68-80.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026 01 15; 147(3):276-289.
-
Dual MAPK/VEGF inhibition for KRAS-mutated brain arteriovenous malformations. J Neurosurg. 2026 Feb 01; 144(2):452-461.